Clinical Trial Update: A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. [Phase 2]

View source ↗

Summary

Pfizer is conducting a Phase 2 trial to evaluate ritlecitinib as a potential treatment for chronic spontaneous urticaria in adults; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: RECRUITING